Literature DB >> 28709671

Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives.

Kiran Sapkota1, Mark W Irvine2, Guangyu Fang2, Erica S Burnell2, Neil Bannister2, Arturas Volianskis3, Georgia R Culley1, Shashank M Dravid4, Graham L Collingridge5, David E Jane2, Daniel T Monaghan6.   

Abstract

The theory that N-methyl-d-aspartate receptor (NMDAR) hypofunction is responsible for the symptoms of schizophrenia is well supported by many pharmacological and genetic studies. Accordingly, positive allosteric modulators (PAMs) that augment NMDAR signaling may be useful for treating schizophrenia. Previously we have identified several NMDAR PAMs containing a carboxylic acid attached to naphthalene, phenanthrene, or coumarin ring systems. In this study, we describe several functional and mechanistic properties of UBP684, a 2-naphthoic acid derivative, which robustly potentiates agonist responses at each of the four GluN1a/GluN2 receptors and at neuronal NMDARs. UBP684 increases the maximal l-glutamate/glycine response while having minor subunit-specific effects on agonist potency. PAM binding is independent of agonist binding, and PAM activity is independent of membrane voltage, redox state, and the GluN1 exon 5 N-terminal insert. UBP684 activity is, however, markedly pH-dependent, with greater potentiation occurring at lower pHs and inhibitory activity at pH 8.4. UBP684 increases channel open probability (Po) and slows receptor deactivation time upon removal of l-glutamate, but not glycine. The structurally related PAM, UBP753, reproduced most of these findings, but did not prolong agonist removal deactivation time. Studies using cysteine mutants to lock the GluN1 and GluN2 ligand-binding domains (LBDs) in the agonist-bound states indicate that PAM potentiation requires GluN2 LBD conformational flexibility. Together, these findings suggest that UBP684 and UBP753 stabilize the GluN2 LBD in an active conformation and thereby increase Po. Thus, UBP684 and UBP753 may serve as lead compounds for developing agents to enhance NMDAR activity in disorders associated with NMDAR hypofunction.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Deactivation; Ligand-binding domain; N-methyl-d-aspartate; Positive allosteric modulator; Potentiator; l-glutamate

Mesh:

Substances:

Year:  2017        PMID: 28709671      PMCID: PMC5623084          DOI: 10.1016/j.neuropharm.2017.07.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  65 in total

1.  Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel.

Authors:  K Ikeda; M Nagasawa; H Mori; K Araki; K Sakimura; M Watanabe; Y Inoue; M Mishina
Journal:  FEBS Lett       Date:  1992-11-16       Impact factor: 4.124

2.  Developmental changes in distribution of NMDA receptor channel subunit mRNAs.

Authors:  M Watanabe; Y Inoue; K Sakimura; M Mishina
Journal:  Neuroreport       Date:  1992-12       Impact factor: 1.837

Review 3.  The glutamate receptor ion channels.

Authors:  R Dingledine; K Borges; D Bowie; S F Traynelis
Journal:  Pharmacol Rev       Date:  1999-03       Impact factor: 25.468

4.  Transmitter timecourse in the synaptic cleft: its role in central synaptic function.

Authors:  J D Clements
Journal:  Trends Neurosci       Date:  1996-05       Impact factor: 13.837

Review 5.  Excitatory amino acid transmitters.

Authors:  J C Watkins; R H Evans
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

6.  Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.

Authors:  T Ishii; K Moriyoshi; H Sugihara; K Sakurada; H Kadotani; M Yokoi; C Akazawa; R Shigemoto; N Mizuno; M Masu
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

7.  Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.

Authors:  Blaise Mathias Costa; Mark W Irvine; Guangyu Fang; Richard J Eaves; Maria Belen Mayo-Martin; Bodo Laube; David E Jane; Daniel T Monaghan
Journal:  Neuropharmacology       Date:  2011-12-06       Impact factor: 5.250

Review 8.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

Review 9.  Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.

Authors:  Eleni Koutsilieri; Peter Riederer
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

10.  Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known NMDA Receptor Allosteric Modulators.

Authors:  Mark W Irvine; Guangyu Fang; Daniel T Monaghan; David E Jane; Richard Eaves; Maria B Mayo-Martin; Erica S Burnell; Blaise M Costa; Georgia R Culley; Arturas Volianskis; Graham L Collingridge
Journal:  Synthesis (Stuttg)       Date:  2015-06-01       Impact factor: 3.157

View more
  6 in total

1.  The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.

Authors:  Kiran Sapkota; Kim Dore; Kang Tang; Mark Irvine; Guangyu Fang; Erica S Burnell; Roberto Malinow; David E Jane; Daniel T Monaghan
Journal:  Biochem Pharmacol       Date:  2018-11-29       Impact factor: 5.858

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

3.  Differential regulation of STP, LTP and LTD by structurally diverse NMDA receptor subunit-specific positive allosteric modulators.

Authors:  G France; R Volianskis; R Ingram; N Bannister; R Rothärmel; M W Irvine; G Fang; E S Burnell; K Sapkota; B M Costa; D A Chopra; S M Dravid; A T Michael-Titus; D T Monaghan; J Georgiou; Z A Bortolotto; D E Jane; G L Collingridge; A Volianskis
Journal:  Neuropharmacology       Date:  2021-10-20       Impact factor: 5.250

Review 4.  Protein quality control of N-methyl-D-aspartate receptors.

Authors:  Taylor M Benske; Ting-Wei Mu; Ya-Juan Wang
Journal:  Front Cell Neurosci       Date:  2022-07-22       Impact factor: 6.147

Review 5.  Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Authors:  Erica S Burnell; Mark Irvine; Guangyu Fang; Kiran Sapkota; David E Jane; Daniel T Monaghan
Journal:  J Med Chem       Date:  2018-03-05       Impact factor: 7.446

6.  Higher ambient synaptic glutamate at inhibitory versus excitatory neurons differentially impacts NMDA receptor activity.

Authors:  Lulu Yao; Teddy Grand; Jesse E Hanson; Pierre Paoletti; Qiang Zhou
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.